EUCTR2014-002841-23-ES进行中（未招募）1 期
A Phase I/IIa Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With Respiratory Syncytial Virus Lower Respiratory Tract Infection, Consisting of an Open-label Lead in Part Followed by a Double-blind, Placebo-controlled Part, to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171, Administered Via Inhalation, in Addition to Standard of Care
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Ablynx NV
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject is a male or female infant or toddler aged 5 months to < 24 months.
- •2. Subject is otherwise healthy, but hospitalised for and clinically diagnosed with RSV LRTI (bronchiolitis or broncho-pneumonia), i.e., showing typical clinical signs and symptoms such as tachypnoea, wheezing, cough, crackles, use of accessory muscles, and/or nasal flaring.
- •3. Subject has appearance of upper or lower respiratory tract infection symptoms that are likely related to RSV infection (e.g., rhinitis) within ? 4 days at the time of screening.
- •4. Subject has a positive RSV diagnostic test .
- •5. Subject is expected to have to stay in the hospital for at least 24 hours (according to the Investigator?s judgement at screening).
- •6. Subject has normal psychomotor development (according to the Investigator?s judgement at screening).
- •7. Subject?s gestational age was > 37 weeks.
- •8. Parent(s)/legal guardian(s) are able and willing to provide written informed consent.
- •9. The subject and parent(s)/legal guardian(s) are able and willing to comply with the study protocol.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 35
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subject has history of wheezing (i.e., >3 previous episodes of wheezing), as reported by the parent(s)/legal guardian(s), or according to the Investigator?s judgement at screening.
- •2. Subject is known to have significant comorbidities, including gastro-oesophageal reflux disease, genetic disorders (e.g., trisomy 21), cardiopulmonary diseases (e.g., haemodynamically significant congenital heart disease, or bronchopulmonary dysplasia), any hereditary or acquired metabolic (bone) diseases, haematological or other malignancy, or is known to be human immunodeficiency virus (HIV) positive.
- •3. Subject is known to be immunocompromised.
- •4. Subject has any presence of active moderate to severe atopic dermatitis (according to the Investigator?s judgement at screening).
- •5. Subject has any known history or presence of food allergy.
- •6. Subject is suspected of having a clinically relevant infection other than RSV.
- •7. Subject has a history of any ventilation or respiratory support, including the neonatal period.
- •8. Subject has significant oral and/or maxillofacial malformations.
- •9. Subject is critically ill and/or is expected to require invasive mechanical ventilation or noninvasive respiratory support (e.g., continuous or bilevel positive airway pressure) within 24 hours (according to the Investigator?s judgement at screening), with the exception of O2 supplementation via nasal cannula, simple face mask, or headbox.
- •10. Subject has received 1 or more doses of palivizumab at any time prior to screening, or has received treatment with any antiviral therapy for RSV (e.g., ribavirin or i.v. immunoglobulin) within 1 month prior to screening.
- •11. Subject has received corticosteroids (inhaled/oral) less than 30 days prior to screening.
- •12. Subject is being treated with antibiotics and needs continued antibiotic therapy. Note that subjects receiving antibiotics at screening will not be excluded if the antibiotics can be safely stopped according to the Investigator?s judgement. The initiation of antibiotic therapy during the study is allowed.
- •13. Subject is currently participating in any investigational study.
研究者
相似试验
已完成
2 期
A multicenter phase II study for previouly untreated advanced stage peripheral T-cell lymphoma evaluating efficacy and safety of combination chemotherapy with THP-COP regimepreviouly untreated advanced stage peripheral T-cell lymphomaJPRN-UMIN000014902Hematological Malignancy Study Group40
已完成
不适用
A phase I-Ib/II, open-label, multi-center study of the safety and efficacy of MBG453 as single agent and in combination with PDR001 in adult patients with advanced malignanciesmelanomaadvanced cancerlungcancer10027655NL-OMON53097ovartis33
进行中（未招募）
1 期
An interventional study of MBG453 as single agent and in combination with PDR001 in patients with advanced malignanciesSolid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2015-002354-12-NLovartis Pharma Services AG252
进行中（未招募）
1 期
An interventional study of MBG453 alone and in combination with PDR001 in patients with advanced malignanciesSolid tumorsEUCTR2015-002354-12-DEovartis Pharma Services AG250
已完成
1 期
Phase I-Ib/II study of MBG453 as single agent and in combination with PDR001 in patients with advanced malignancies.advanced solid tumorJPRN-jRCT2080223302ovartis Pharma. K.K.21